[ad_1]
DUBLIN, Oct. 27, 2022 /PRNewswire/ — The “Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type, Application, Distribution Channel, End User, and Geography” report has been added to ResearchAndMarkets.com’s offering.
The Intravenous Immunoglobulin market was valued at US$ 11,206.54 million in 2021 and is expected to reach value of US$ 18,672.55 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.
Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.
According to the National Institute of Allergy and Infectious Diseases (NIAID), over 200 different types of primary immune deficiency diseases (PIDDs) affect about 500,000 people in the US.
Intravenous Immunoglobulin Market: Segmental Overview
Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG type immunoglobulin segment will hold the largest market share in 2021. However, the handheld segment is anticipated to register the highest CAGR during the forecast period owing to its wide application of IgG in treating several disorders.
Based on application, the intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. In 2021, the immunodeficiency diseases segment will likely hold the market’s largest share. Moreover, the same segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028 due to the rising prevalence of immunodeficiency diseases and increasing FDA approvals for IVIg products to . ..
Full story available on Benzinga.com
[ad_2]
Source link
